Skip to main content
PLIANT THERAPEUTICS, INC. logo

PLIANT THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PLRX ISIN · US7291391057 LEI · 5493002Q5LITR7VHZH02 US Professional, scientific and technical activities
Open in API
Filings indexed 403 across all filing types
Latest filing 2021-03-18 Director's Dealing
Country US United States of America
Listing US PLRX

About PLIANT THERAPEUTICS, INC.

https://pliantrx.com/

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of fibrosis and related diseases. The company leverages its expertise in integrin biology to create tissue-specific treatments. Its therapeutic approach centers on modulating integrin activity and inhibiting TGF-β1 signaling, which are key molecular drivers of fibrosis. Pliant utilizes its proprietary discovery platform to advance a pipeline of integrin-based product candidates, aiming to provide safer and more effective therapies for patients.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-03-18 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans. It includes details about the securities to be registered, the registration fee, incorporation by reference of other filings (like the Annual Report on Form 10-K), and indemnification provisions for directors and officers. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits the category of Regulatory Filings (RNS). The document length and content confirm it is a full registration statement, not a brief announcement or certification.
2021-03-16 English
10-K
Annual Report FY 2020
2021-03-16 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 16, 2021, by Pliant Therapeutics, Inc. It announces the release of the company's financial results for the fourth quarter and year ended December 31, 2020, via a press release attached as Exhibit 99.1. The text explicitly states that the press release is furnished as an exhibit and incorporated by reference, and the document itself does not contain detailed financial statements or substantive financial data. The document is relatively short (3622 characters) and serves as a notification of the earnings release rather than the earnings release itself. According to the classification rules, such a document is best classified as an Earnings Release (ER) since it announces quarterly/year-end financial results highlights through a press release. The document is not a full annual report (10-K), interim report (IR), or a regulatory filing (RNS) because it specifically relates to financial results announcement. Therefore, the appropriate classification is ER with high confidence.
2021-03-16 English
FORM 4 SUBMISSION
Director's Dealing
2021-03-06 English
CHI ADVISORS LLC
Major Shareholding Notification
2021-03-02 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.